Dr Xiao-Ning Xu qualified in Medicine from Capital Medical University (Beijing) in 1984 and obtained a PhD in Clinical Immunology in 1992 from Flinders Medical Centre (Australia) and became the fellow of the Royal College of Pathologists of Australasia (FRCPA) in 1999. He then joined the group of Prof Sir Andrew J. McMichael as NHMRC research fellow at Weatherall Institute of Molecular Medicine, University of Oxford.
Over the last two decades, Xiao-Ning served as Medical Research Council (MRC) Senior Clinical Scientist, project leader, and tenured programme leader at MRC Human Immunology Unit, Oxford University, where he led research projects involving immune correlates of protection against emerging infectious diseases including HIV, SARS, and avian influenza. In 2010, he joined Novartis as the Head of Novartis Vaccines Research China, Novartis Vaccines & Diagnostics based in Shanghai, and in 2013 he became the Chair professor in Human Immunology at the Imperial College London based at Chelsea & Westminster Hospital.
et al., 2019, Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans, Cell Reports
et al., 2018, Strategies for an HIV cure: progress and challenges, Nature Immunology, Vol:19, ISSN:1529-2908, Pages:1155-1158
Kelleher P, Xu X-N, 2018, Hard-to-kill macrophages lead to chronic inflammation in HIV., Nat Immunol, Vol:19, Pages:433-434
et al., 2017, The role of vaccines and vaccine decision-making to achieve the goals of the Grand Convergence in public health., Vaccine, Vol:35 Suppl 1, Pages:A10-A15
et al., 2016, Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus, Science Translational Medicine, Vol:8, ISSN:1946-6234
et al., 2016, Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions, Proceedings of the National Academy of Sciences of the United States of America, Vol:113, ISSN:1091-6490, Pages:5682-5687
et al., 2014, Virus-Specific Antibody Secreting Cell, Memory B-cell, and Sero-Antibody Responses in the Human Influenza Challenge Model, Journal of Infectious Diseases, Vol:209, ISSN:0022-1899, Pages:1354-1361
Li CK-F, Rappuoli R, Xu X-N, 2013, Correlates of protection against influenza infection in humans - on the path to a universal vaccine?, Current Opinion in Immunology, Vol:25, ISSN:0952-7915, Pages:470-476
et al., 2012, HLA-B may be more protective against HIV-1 than HLA-A because it resists negative regulatory factor (Nef) mediated down-regulation, Proceedings of the National Academy of Sciences of the United States of America, Vol:109, ISSN:0027-8424, Pages:13353-13358
et al., 2012, Preexisting influenza-specific CD4(+) T cells correlate with disease protection against influenza challenge in humans, Nature Medicine, Vol:18, ISSN:1078-8956, Pages:274-280
et al., 2011, Identification of Self-lipids Presented by CD1c and CD1d Proteins, Journal of Biological Chemistry, Vol:286, ISSN:0021-9258, Pages:37692-37701
et al., 2008, T cell responses to whole SARS coronavirus in humans, Journal of Immunology, Vol:181, ISSN:0022-1767, Pages:5490-5500